Squarepoint Ops LLC Inhibrx, Inc. Transaction History

Squarepoint Ops LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $507,935 - $833,181	-29,949 Reduced 68.99%	13,460 $349,000
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $518,629 - $762,905	28,110 Added 183.74%	43,409 $819,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $14,771 - $24,397	732 Added 5.03%	15,299 $376,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $726,158 - $1.55 Million	-62,708 Reduced 81.15%	14,567 $261,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $560,249 - $1.66 Million	65,757 Added 570.91%	77,275 $877,000

Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $229,093 - $497,347	11,518 New	11,518 $257,000

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.